4,4-Disubstituted piperidine high-affinity NK1 antagonists: Structure- activity relationships and in vivo activity

Journal of Medicinal Chemistry

Volumn 41, Issue 23, 1998, Pages 4623-4635

  Stevenson, Graeme I ^a   Huscroft, Ian ^a   MacLeod, Angus M ^a   Swain, Christopher J ^a   Cascieri, Margaret A ^b   Chicchi, Gary G ^b   Graham, Michael I ^a   Harrison, Timothy ^a   Kelleher, Fintan J ^a   Kurtz, Marc ^b   Ladduwahetty, Tamara ^a   Merchant, Kevin J ^a   Metzger, Joseph M ^b   MacIntyre, D E ^b   Sadowski, Sharon ^b   Sohal, Balbinder ^a   Owens, Andrew P ^a  

^a NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (METHYLSULFONYL) 4 PHENYL 4 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXYMETHYL]PIPERIDINE; 1 [4 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXYMETHYL] 4 PHENYLPIPERIDINE 1 YL] PYRROLIDINEACETAMIDE 4 TOLUENE SULFONATE; 1 ACETYL 4 PHENYL 4 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXYMETHYL]PIPERIDINE; 2 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 4 (3 OXO 1,2,4 TRIAZOL 5 YLMETHYL) 3 PHENYLMORPHOLINE; 2 BENZHYDRYL 3 (2 METHOXYBENZYLAMINO) 1 AZABICYCLO[2.2.2]OCTANE; 3 (2 METHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 3 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 2 PHENYLPIPERIDINE; 4 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXYMETHYL] 1 (2 METHYLTHIAZOL 5 YLMETHYL) 4 PHENYLPIPERIDINE; 4 PHENYL 4 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXYMETHYL]PIPERIDINE; 5 [[3 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 2 PHENYL 1 PIPERIDINYL]METHYL] 1,2 DIHYDRO 3H 1,2,4 TRIAZOL 3 ONE; [2 METHOXY 5 (1 TETRAZOLYL)BENZYL](2 PHENYL 3 PIPERIDINYL)AMINE; N ACETYLTRYPTOPHAN 3,5 BIS(TRIFLUOROMETHYL)BENZYL ESTER; NEUROKININ 1 RECEPTOR ANTAGONIST; NOLPITANTIUM; PIPERIDINE DERIVATIVE; RESINIFERATOXIN; SUBSTANCE P; SUBSTANCE P ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG COMPETITION; DRUG CONFORMATION; DRUG RECEPTOR BINDING; GUINEA PIG; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; RECEPTOR AFFINITY; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ANIMALS; CAPILLARY PERMEABILITY; CHO CELLS; CRICETINAE; DITERPENES; ESOPHAGUS; GUINEA PIGS; INOSITOL PHOSPHATES; MALE; PIPERIDINES; PYRROLIDINES; RADIOLIGAND ASSAY; RECEPTORS, NEUROKININ-1; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 15444342053     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980376b     Document Type: Article

References (39)

1. Snider, R. M.; Constantine, J. W.; Lowe, J. A.; Longo, K. P.; Lebel, W. S.; Woody, H. A.; Drozda, S. E.; Desai, M. C.; Vinick, F. J.; Spencer, R. W.; Hess, H. J. A Potent Non-Peptide Antagonist of the Substance P (NK1) Receptor. Science 1991, 251, 435-437.
2. (a) Desai, M. C.; Lefkowitz, S. L.; Thadeio, P. F.; Longo, K. P.; Snider, R. M. Discovery of a Potent Substance P Antagonist: Recognition of the Key Molecular Determinant. J. Med. Chem. 1992, 35, 4911-4913.
3. (b) McLean, S.; Snider, R. M.; Desai, M. C.; Rosen, T.; Bryce, D. K.; Longo, K. P.; Schmidt, A. W.; Heym, J. CP-99,994, A Nonpeptide Antagonist of the Tachykinin NK1 Receptor. Regulat. Pept. 1993, 46, 329-331.
4. (c) McLean, S.; Ganong, A.; Seymour, P. A.; Snider, R. M.; Desai, M. C.; Rosen, T.; Bryce, D. K.; Longo, K. P.; Reynolds, L. S.; Robinson, G.; Schmidt, A. W.; Siok, C.; Heym, J. Pharmacology of CP-99,994; A Nonpeptide Antagonist of the Tachykinin Neurokinin-1 Receptor. J. Pharmacol. Exp. Ther. 1993, 267, 472-479.
5. (d) Lowe, J. A., III. Nonpeptide tachykinin antagonists: Medicinal Chemistry and molecular biology. Med. Res. Rev. 1996, 16 (6), 527-545.
6. 1 antagonists as observed in their crystal structures. Bioorg. Med. Chem. 1997, 5 (3), 535-547.
7. Ward, P.; Armour, D. R.; Bays, D. E.; Evans, B.; Giblin, G. M. P.; Heron, N.; Hubbard, T.; Liang, K.; Middlemiss, D.; Mordaunt, J.; Naylor, A.; Pegg, N. A.; Vinader, V.; Watson, S. P.; Bountra, C.; Evans, D. C. Discovery of an Orally Bioavailable NK-1 Receptor Antagonist, (2S, 3S)-(2-Methoxy-5-tetrazol-l-ylbenzyl)(2-phenylpiperidm-3-yl)amine (GR203040), with Potent Antiemetic Activity. J. Med. Chem. 1995, 38, 4985-4992.
8. 1 Antagonists: Determination of the Relative and Absolute Stereochemical Requirements. Bioorg. Med. Chem. Lett. 1994, 4 (21), 2545-2550.
9. 1 Antagonists. J. Med. Chem. 1996, 39, 2907-2914.
10. Hale, J. J.; Mills, S. G.; MacCoss, M.; Shah, S. K.; Qi, H.; Mathre, D. J.; Cascieri, M. A.; Sadowski, S.; Strader, C. D.; MacIntyre, D. E.; Metzger, J. M. (2-(S)-(3,5-bis(trifluoromethyl)benzyloxy-3-(S)-phenyl-4-(5-(3-oxo-1,2,4- triazolo)methylmorpholine, A Potent, Orally Active, Morpholine-Based Human NK-1 Receptor Antagonist. J. Med. Chem. 1996, 39, 1760-1762.
11. MacLeod, A. M.; Merchant, K. J.; Brookfield, F.; Lewis, R.; Kelleher, F.; Stevenson, G.; Owens, A.; Swain, C. J.; Baker, R.; Cascieri, M. A.; Sadowski, S.; Ber, E.; MacIntyre, D. E.; Metzger, J.; Ball, R. N-Acyl Tryptophan Benzyl Esters: Potent Substance P Antagonists. J. Med. Chem. 1993, 36, 2044-2045.
12. 1 Receptor. Neuropeptides 1993, 24, 233.
13. (a) Fong, T. M.; Anderson, S. A.; Yu, H.; Huang, R. R. C.; Strader, C. D. Differential activation of intracelluar effectors by two isoforms of human neurokinin-1 receptor. Mol. Pharmacol. 1992, 41, 24-30.
14. (b) Takeda, Y.; Chou, K. B.; Takeda, J.; Sachais, B. S.; Krause, J. E. Molecular cloning, structural characterisation and functional expression of the human Substance P receptor. Biochem. Biophys. Res. Commun. 1991, 179, 1232-1240.
15. Barnes, P. J. Neurogenic Inflamation in Airways and its Modulation. Arch. Int. Pharmacodyn. 1990, 303, 67-82. See also: Lotz, M.; Vaughan, J. H.; Carson, D. A. Effect of Neuropeptides on Production of Inflammatory Cytokines by Human Monocytes. Science 1988, 241, 1218-1221.
16. Barnes, P. J. Neurogenic Inflamation in Airways and its Modulation. Arch. Int. Pharmacodyn. 1990, 303, 67-82. See also: Lotz, M.; Vaughan, J. H.; Carson, D. A. Effect of Neuropeptides on Production of Inflammatory Cytokines by Human Monocytes. Science 1988, 241, 1218-1221.
17. Otsuka, M.; Yanigasawa, M. Effect of a Tachykinin Antagonist on a Nociceptive Reflex in the Isolated Spinal Cord-Tail preparation of the Newborn Rat. J. Physiol. (London) 1988, 395, 255-270.
18. Pernow, B.; Rosell, S. Effect of Substance P on Blood Flow in Canine Adipose Tissue and Skeletal Muscle. Acta Physiol. Scand. 1975, 93, 139-141.
19. Barnes, P. J. Asthma as an Axon Reflex. Lancet 1986, 242-244.
20. Perianin, A.; Snyderman, R.; Malfroy, B. Substance P Primes Human Neutrophil Activation: A Mechanism for Neurological Regulation of Inflammation. Biochem. Biophys. Res. Commun. 1989, 161, 520-524.
21. (a) Shepheard, S. L.; Williamson, D. W.; Hill, R. G.; Hargreaves, R. J. The Non-peptide Neurokinini Receptor Antagonist RP 76580 Blocks Neurogenic Plasma Extravasation in the Dura Mater of Rats. Br. J. Pharmacol 1993, 108, 11-12.
22. 1 Antagonist CP-99,994 on Plasma Extravasation in Dura Mater and c-fos mRNA Expression in Trigeminal Caudalis of Rats. Neuropharmacology 1995, 34 (3), 255-261.
23. 1 Antagonist CP-99,994 Attenuates Cisplatin Indued Emesis in the Ferret. Eur. J. Pharmacol. 1993, 250, R5-R6.
24. 1 Receptor. Br. J. Pharmacol. 1995, 115, 84-94.
25. 1 Receptor Antagonists are Centrally Mediated. Can. J. Physiol. Pharmacol. 1994, 72 (Suppl. 2), 45.
26. 1 receptor antagonists. Eur. J. Pharmacol. 1996, 326 (2/3), 201-209.
27. 2+ channels. Eur. J. Pharmacol. 1992, 215, 351-352.
28. (b) Constantine, J. W.; Lebel, W. S.; Woody, H. A.; Benoit, P. A.; Woolfgang, E. A.; Knight, D. R. Cardiovascular Effects of CP-96,345, A Non-Peptide Blocker of Tachykinin Receptors. Eur. J. Pharmacol. 1994, 252, 275-282.
29. 1 antagonists 2: Investigation of the Effect of N-substitution. Bioorg. Med. Chem. Lett. 1995, 5, 209-212.
30. (d) Baker, R.; Harrison, T.; Swain, C. J.; Williams, B. J. PCT WO93/04040, 1993.
31. 1 Antagonist. J. Med. Chem. 1995, 38, 1264-1266.
32. 1 Antagonists I: 3-Benzyloxy-1-azabicyclo-[2.2.2]octanes. Bioorg. Med. Chem. Lett. 1993, 3 (6), 1361-1366.
33. 1 Antagonists: Replacements for the Benzhydryl Group. Bioorg. Med. Chem. Lett. 1994, 4 (18), 2161-2164.
34. Harrison, T.; Williams, B. J.; Swain, C. J. Gem-Disubstituted Amino-Ether Based Substance P Antagonists. Bioorg. Med. Chem. Lett. 1994, 4, 2733-2734.
35. Cascieri, M. A.; Ber, E.; Fong, T. M.; Sadowski, S.; Bansal, A.; Swain, C. J.; Seward, E. M.; Frances, B.; Burns, D.; Strader, C. D. Characterisation of the Binding of a Potent, Selective Radio-iodinated Antagonist to the Human Neurokinin-1 Receptor. Mol. Pharmacol. 1992, 42, 458-463.
36. Hart, P. A.; Rich, D. Stereochemical aspects of drug action I: Conformational restriction, steric hindrance and hydrophobic collapse. Pract. Med. Chem. 1996, 393-412.
37. Fong, T. M.; Huang, R. R.; Yu, H.; Swain, C. J.; Underwood, D.; Cascieri, M. A.; Strader, C. D. Mutational analysis of neurokinin receptor function. Can. J. Physiol. Pharmacol. 1995, 73 (7), 860-5.
38. 1) Antagonist, CP-96,345. Bioorg. Med. Chem. Lett. 1992, 2, 559-564.
39. 1 Receptor Antagonists Act Centrally to Inhibit Emesis Induced by the Chemotherapeutic Agent Cisplatin in Ferrets. Neuropharmacology 1996, 35 (8), 1121-1129.